MARKET

MNOV

MNOV

Medicinova
NASDAQ
1.420
-0.010
-0.70%
Closed 16:00 05/17 EDT
OPEN
1.400
PREV CLOSE
1.430
HIGH
1.450
LOW
1.350
VOLUME
8.95K
TURNOVER
0
52 WEEK HIGH
2.660
52 WEEK LOW
1.260
MARKET CAP
69.65M
P/E (TTM)
-8.2799
1D
5D
1M
3M
1Y
5Y
MEDICINOVA - GETS NOTICE OF ALLOWANCE FOR NEW PATENT COVERING MN-166 (IBUDILAST) FOR TREATING CHLORINE-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME
Reuters · 5d ago
Weekly Report: what happened at MNOV last week (0506-0510)?
Weekly Report · 6d ago
Medicinova, Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 05/10 21:02
MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024
MediciNova reported earnings per share of -6 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -5 cents. Medici nova also reported results for the fourth quarter of 2015.
Investorplace · 05/10 12:52
MediciNova: Q1 Earnings Snapshot
MediciNova Inc. Reported a loss of $2.8 million in its first quarter. On a per-share basis, the La Jolla, California-based company said it had a lost of 6 cents. The company reported a profit of $1.7 million in the quarter.
Barchart · 05/09 18:44
MediciNova anti-inflammatory drug gets issue notification for new patent
MediciNova anti-inflammatory drug gets issue notification for new patent. MN-166 (ibudilast) is in late-stage clinical development for the treatment of neurodegenerative diseases. The new patent is expected to expire no earlier than September 2040.
Seeking Alpha · 05/07 10:46
MEDICINOVA INC - NEW PATENT IS EXPECTED TO EXPIRE NO EARLIER THAN SEPTEMBER 2040
Reuters · 05/07 10:00
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
MediciNova, Inc. Has received a new patent for extended-release oral formulations of MN-166 (ibudilast) This new patent is expected to expire no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule.
Barchart · 05/07 05:00
More
About MNOV
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Webull offers Medicinova Inc stock information, including NASDAQ: MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.